PubTransformer

A site to transform Pubmed publications into these bibliographic reference formats: ADS, BibTeX, EndNote, ISI used by the Web of Knowledge, RIS, MEDLINE, Microsoft's Word 2007 XML.

Regional Variability in Percentage of Breast Cancers Reported as Positive for HER2 in California: Implications of Patient Demographics on Laboratory Benchmarks.

Abstract The expected regional variability in percent human epidermal growth factor receptor 2 (HER2)-positive breast cancers is not currently clear.
PMID
Related Publications
Authors

Mayor MeshTerms
Keywords

Benchmark

Breast cancer

HER2

Positivity rate

Quality

Variability

Journal Title american journal of clinical pathology
Publication Year Start




PMID- 28821197
OWN - NLM
STAT- In-Process
DA  - 20170819
LR  - 20170819
IS  - 1943-7722 (Electronic)
IS  - 0002-9173 (Linking)
VI  - 148
IP  - 3
DP  - 2017 Sep 01
TI  - Regional Variability in Percentage of Breast Cancers Reported as Positive for
      HER2 in California: Implications of Patient Demographics on Laboratory
      Benchmarks.
PG  - 199-207
LID - 10.1093/ajcp/aqx063 [doi]
AB  - Objectives: The expected regional variability in percent human epidermal growth
      factor receptor 2 (HER2)-positive breast cancers is not currently clear. Methods:
      Data from the 2006 to 2011 California Cancer Registry were examined by county and
      health service area. The influence of demographic and pathologic features was
      used in a multivariable logistic regression model to compare expected with
      observed HER2-positive percentages by region. Results: There was significant
      geographic variation by California counties (11.6%-26%). The reported
      HER2-positive percentage was higher when the population had higher stage, tumor
      size, grade, percent estrogen receptor negative, younger age, or lower
      socioeconomic status. Ethnic distribution of the population also influenced
      HER2-positive percentages. Using a multivariable logistic regression model, most 
      regions had expected values based on their population characteristics; however,
      "outlier" regions were identified. Conclusions: These results deepen our
      understanding of population characteristics' influence on the distribution of
      HER2-positive breast cancers. Taking these factors into account can be useful
      when setting laboratory benchmarks and assessing test quality.
FAU - Lin, Chieh-Yu
AU  - Lin CY
AD  - Department of Pathology.
FAU - Carneal, Eugene E
AU  - Carneal EE
AD  - Department of Pathology.
FAU - Lichtensztajn, Daphne Y
AU  - Lichtensztajn DY
AD  - Cancer Prevention Institute of California, Fremont, CA.
FAU - Gomez, Scarlett L
AU  - Gomez SL
AD  - Cancer Prevention Institute of California, Fremont, CA.
AD  - Stanford Cancer Institute, Stanford, CA.
FAU - Clarke, Christina A
AU  - Clarke CA
AD  - Cancer Prevention Institute of California, Fremont, CA.
AD  - Stanford Cancer Institute, Stanford, CA.
FAU - Jensen, Kristin C
AU  - Jensen KC
AD  - Department of Pathology.
AD  - VA Palo Alto Health Care System, Palo Alto, CA.
FAU - Kurian, Allison W
AU  - Kurian AW
AD  - Departments of Medicine and Health Research & Policy, Stanford University School 
      of Medicine, Stanford, CA.
FAU - Allison, Kimberly H
AU  - Allison KH
AD  - Department of Pathology.
LA  - eng
PT  - Journal Article
PL  - England
TA  - Am J Clin Pathol
JT  - American journal of clinical pathology
JID - 0370470
OTO - NOTNLM
OT  - Benchmark
OT  - Breast cancer
OT  - HER2
OT  - Positivity rate
OT  - Quality
OT  - Variability
EDAT- 2017/08/20 06:00
MHDA- 2017/08/20 06:00
CRDT- 2017/08/20 06:00
AID - 4080647 [pii]
AID - 10.1093/ajcp/aqx063 [doi]
PST - ppublish
SO  - Am J Clin Pathol. 2017 Sep 1;148(3):199-207. doi: 10.1093/ajcp/aqx063.